FDA Approves First Treatment for Global problem��, is GILD a BUY? Veklury (remdesivir) research. Investment Club |
- FDA Approves First Treatment for Global problem��, is GILD a BUY? Veklury (remdesivir) research.
- Explanatory video of the difference between trading and investing, are you a trader or investor?
- CRISPR: The four public companies EDIT, NTLA, CRSP and BEAM
- Eat Just Seeks New Funding
- �� NQ 100 at Equilibrium but Final Bearish Wave C Remains ��
- Chinese parental Gland Pharma received green signal from SEBI to raise Rs. 6,000 crores
- Quibi Bites The Dust
- Tekion Lands $150M Round
- Arctic Wolf Scores $200M Round
- What is the best investment according to you?
- 3 filters which investors should not avoid while selecting a stock for portfolio
- 4 Investment Philosophies followed by UHNIs
- Bob Iger Joins Perfect Day Board
- SP500 Analysis: Are We Starting A Stock Market Crash? (Bonds, Dollar Index Rallying)
- Tesla bonds analysis: low default risk, but beware of the share price - Finance Drops
- “Analyst Buy Ratings” Why You Shouldn’t Trust Them
- MBIO Stock Analysis��, is Mustang Bio a BUY?
- I interviewed the CEO of Zubr, a hyper-fast derivatives exchange aimed towards institutional investors. Hope you guys like it!
- The Double Edged Sword to our Monetary Future
- Billionaire Ray Dalio Predicts NEW WORLD ORDER | What Will Happen Next is Shocking
- ThredUp Files To Go Public
- Time In The Market Vs Timing The Market (Which is better?)
| FDA Approves First Treatment for Global problem��, is GILD a BUY? Veklury (remdesivir) research. Posted: 23 Oct 2020 10:58 AM PDT
 | ||
| Explanatory video of the difference between trading and investing, are you a trader or investor? Posted: 23 Oct 2020 08:42 AM PDT
 | ||
| CRISPR: The four public companies EDIT, NTLA, CRSP and BEAM Posted: 22 Oct 2020 02:57 PM PDT With the recent Nobel Prize in chemistry being awarded to the pioneers in the field I thought it could be interesting write a small updated article for those who never heard of it and why it is such a huge opportunity. https://abcnews.go.com/Technology/wireStory/panel-announce-2020-nobel-prize-chemistry-73466890 What is CRISPR, how does it work, who does what? https://www.youtube.com/watch?v=jAhjPd4uNFY (Video recommended) https://en.wikipedia.org/wiki/CRISPR Basically every living organism is comprised of a DNA code that determines its layout based on 4 'letters' (amino acids ATCG). CRISPR related tech allows you to change, alter or delete certain parts of that code with relative ease. Hopefully you can imagine the consequences of this little fact, being able to be an architect of life itself. If you can't don't worry others have already done it for you. Intellia Therapeutics pipeline: https://www.intelliatx.com/pipeline-2/ Recent 52week high: CRISPR Therapeutics pipeline: http://www.crisprtx.com/programs/pipeline Recent ATH: https://www.reddit.com/r/CrisprTherapeutics/comments/jcopnr/new_ath_for_crsp/ Editas Medicine pipeline: https://www.editasmedicine.com/gene-editing-pipeline/ 52 week high: https://www.reddit.com/r/EditasMedicine/comments/ep3p8i/edit_reaches_52_week_high/ Beam therapeutics pipeline: https://beamtx.com/our-portfolio/ New kid on the block, IPO'd this year their main approach is using base editing https://www.youtube.com/watch?v=xzlToB_0dNk (Video recommended) Today's ATH: https://www.reddit.com/r/BeamTherapeutics/ In the end which one should you buy, who holds the most promise? Who will win the patent battle? Which method is superior? I've been following the tech for 7 years and I believe all of them will be winners in the end. I can't predict who will win the patent battle, that's why I advice, if you are willing to invest in this sphere to buy all four of them. I'm heavy on EDIT, NTLA & BEAM but that's just me. gl [link] [comments]  | ||
| Posted: 23 Oct 2020 12:18 AM PDT
 | ||
| �� NQ 100 at Equilibrium but Final Bearish Wave C Remains �� Posted: 23 Oct 2020 03:03 AM PDT
 | ||
| Chinese parental Gland Pharma received green signal from SEBI to raise Rs. 6,000 crores Posted: 22 Oct 2020 11:33 PM PDT This is the first time that a Chinese parental drug maker is going to list in the Indian indices. Gland pharma, majority owned by Shanghai Fosun pharmaceutical has received green signal from SEBI to raise 6,000 crores from the new issue market. It's been three years since the Indian equity market has seen any pharma IPO after the Indian drugmaker Eris Lifesciences was listed on the Indian bourses. Despite the ongoing tensions between India and China due to military aggression in the Eastern Ladakh, the market regulator Securities and Executive Board of India (SEBI) has given approval. The issue size of Rs. 6,000 crores is a mix of offer for sale and fresh issue. According to Draft Red Herring Prospectus, the issue comprises of Rs. 1,250 crores to be raised from issuance of fresh equity while the residual amount of Rs. 4,750 crores will be an Offer for Sale. The promoters of the company Fosun Singapore, Gland Celsus, Empoer Trust and Nilay Trust are offloading their stake. U.S.-based Private equity firm KKR is exiting through the offer. Net proceeds from the issue will be utilized for augmenting capital expenditure and taking care of working capital operations in India. [link] [comments]  | ||
| Posted: 22 Oct 2020 05:46 AM PDT
 | ||
| Posted: 22 Oct 2020 02:44 AM PDT
 | ||
| Arctic Wolf Scores $200M Round Posted: 22 Oct 2020 10:36 AM PDT
 | ||
| What is the best investment according to you? Posted: 22 Oct 2020 07:58 AM PDT | ||
| 3 filters which investors should not avoid while selecting a stock for portfolio Posted: 22 Oct 2020 12:44 AM PDT It has always a controversial issue over scrutinization of stocks before adding them in portfolio. No matter which kind of investor you are, which salary class you belong and which ideology provided by market pundits you are banking upon you will always filter the stocks through many funnels before investing into. Phases of investment have changed a lot as the old school of investing have favored for value investing while new school of thought is inclined towards growth stories. But, history has always rewarded only those investors who have relied upon their own thorough analysis rather than following the tips and consultations from market veterans. Equity markets have always demonstrated that an investor cannot turn the table in times when economies are fighting with systematic risk as the concept of diversification get handcuffed and portfolios turn deep red. While, stocks with three important filters discussed below claims to nosedive less during weakness and reverse faster after stagnation. [link] [comments]  | ||
| 4 Investment Philosophies followed by UHNIs Posted: 22 Oct 2020 03:02 AM PDT
 | ||
| Bob Iger Joins Perfect Day Board Posted: 21 Oct 2020 11:42 AM PDT
 | ||
| SP500 Analysis: Are We Starting A Stock Market Crash? (Bonds, Dollar Index Rallying) Posted: 21 Oct 2020 04:49 PM PDT
 | ||
| Tesla bonds analysis: low default risk, but beware of the share price - Finance Drops Posted: 21 Oct 2020 10:04 AM PDT
 | ||
| “Analyst Buy Ratings” Why You Shouldn’t Trust Them Posted: 21 Oct 2020 03:49 PM PDT
 | ||
| MBIO Stock Analysis��, is Mustang Bio a BUY? Posted: 21 Oct 2020 01:04 PM PDT
 | ||
| Posted: 21 Oct 2020 12:37 PM PDT
 | ||
| The Double Edged Sword to our Monetary Future Posted: 21 Oct 2020 11:41 AM PDT
 | ||
| Billionaire Ray Dalio Predicts NEW WORLD ORDER | What Will Happen Next is Shocking Posted: 21 Oct 2020 03:04 PM PDT
 | ||
| Posted: 21 Oct 2020 01:05 PM PDT
 | ||
| Time In The Market Vs Timing The Market (Which is better?) Posted: 21 Oct 2020 12:12 PM PDT
 |
| You are subscribed to email updates from Investment Club. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment